What exactly changed in the ABEO analyst rating on March 09, 2026

Oppenheimer maintained an Outperform rating for Abeona and raised its price target to **$22** on March 09, 2026. The note is the lone rating action recorded that day and was published via StreetInsider.

How should investors interpret an Outperform in the ABEO analyst rating

Outperform in the ABEO analyst rating means the analyst expects Abeona to beat peer performance over the next 12 months. It signals relative confidence but does not eliminate clinical and market risk.

Does the ABEO analyst rating change guarantee stock gains

No. An ABEO analyst rating change is guidance based on research. It can influence sentiment, but clinical results, broader markets, and liquidity determine actual share movement.

Where can I read the Oppenheimer note on ABEO analyst rating

The Oppenheimer price-target update was published via StreetInsider on March 09, 2026 and is available here [source](https://www.streetinsider.com/Analyst+Comments/Abeona+Therapeutics+%28ABEO%29+PT+Raised+to+%2422+at+Oppenheimer/26131433.html).

Analyst Ratings

Oppenheimer Maintains Outperform on Abeona Therapeutics (ABEO) PT $22 March 2026

ByHuzaifa Zahoor March 10, 2026

Oppenheimer maintained an Outperform rating on Abeona Therapeutics Inc. (ABEO) and raised its price target to $22 on March 09, 2026. The ABEO analyst rating note shows firm confidence in Abeona’s outlook despite no immediate price move. This update is the sole analyst action recorded for ABEO on March 09, 2026 and is aimed at positioning investors on valuation and upcoming clinical milestones. Meyka AI’s coverage flagged this as a notable reiteration given the firm’s standing in healthcare research.